Dr. Hashim Raza Kazmi, MD

Dr. Kazmi practices at DaVita Delano Dialysis in Delano, California.

Dr. Kazmi's NPI, 1538270038, was assigned on August 31, 2006. Dr. Kazmi graduated from Dow University of Health Sciences in 1982. Dr. Kazmi holds California license A51606.

Dr. Kazmi's primary practice is DaVita Delano Dialysis, at 405 Dover Parkway, Delano, CA 93215 in Kern County. The practice phone is (661) 725-1323.

Dr. Kazmi's primary practice is DaVita Delano Dialysis in Delano, California. Dr. Kazmi is also affiliated with Adventist Health Delano. The medical group on file is The Nephrology Group, Inc. Dmand AI also links Dr. Kazmi to 4 more hospitals, 4 dialysis centers, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kazmi practices, 12 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Kazmi's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Kazmi is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Kazmi's licenses on file in 5 states: California, Oregon, Michigan, New York and Pennsylvania.

Dmand AI lists acute kidney failure, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Kazmi treats.

CMS data shows 1,460 Medicare services from Dr. Kazmi across 11 procedure codes in 2024, for 504 Medicare patients. Medicare paid $230,405 for them.

CMS counts 504 Medicare patients who saw Dr. Kazmi in 2024. The largest group is 65 to 74, with 184 patients. 75% of them have chronic kidney disease, and 75% have diabetes. 60% are also on Medicaid. Their average risk score is 5.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kazmi's median patient age at 68, with 45% women.

In 2024, Dr. Kazmi wrote 1,501 Medicare Part D claims for 201 patients. 77% of them were for generic drugs. CMS names the drug for 1,352 of them, across 33 drugs with 11 or more claims each, at $311,938 in total drug cost. In 2023, CMS named 1,388 claims across 29 drugs.

Dr. Kazmi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kazmi as offering telehealth.

Dmand AI links Dr. Kazmi to 1 clinical trial. Conditions studied include Hyperphosphatemia and Phosphorus Metabolism Disorders.

CMS Open Payments shows 541 general payments to Dr. Kazmi from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 45% of the total. Horizon Pharma plc paid the most, $40,627.

Dmand AI lists 1 award for Dr. Kazmi, most recently CMS Stage 1 EHR in 2014.

Dr. Kazmi graduated from Dow University of Health Sciences in 1982.

Dr. Kazmi is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.